An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes
NCT ID: NCT03786406
Last Updated: 2023-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2275 participants
OBSERVATIONAL
2018-12-03
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes
NCT03811288
A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal
NCT03797885
Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications
NCT07250607
An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa
NCT05317845
Screening for Undiagnosed Type 2 Diabetes in New Classes of Subjects at High Risk
NCT00520962
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T2DM patients seen in routine practice
All anti-diabetic and cardiovascular (CV) medication will be prescribed at the physician's discretion under routine clinical practice conditions.
No treatment given
No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No treatment given
No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, age greater than or equal to 18 years at the time of signing informed consent
* Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of signing the informed consent
Exclusion Criteria
* Diagnosed with Type 1 diabetes
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
* Patients with known congenital heart disease/malformation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Reporting Anchor and Disclosure (1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Benátky nad Jizerou, , Czechia
Novo Nordisk Investigational Site
Boskovice, , Czechia
Novo Nordisk Investigational Site
Brandýs nad Labem, , Czechia
Novo Nordisk Investigational Site
Břeclav, , Czechia
Novo Nordisk Investigational Site
Chomutov, , Czechia
Novo Nordisk Investigational Site
Hradec Králové, , Czechia
Novo Nordisk Investigational Site
Kroměříž, , Czechia
Novo Nordisk Investigational Site
Olomouc, , Czechia
Novo Nordisk Investigational Site
Orlová, , Czechia
Novo Nordisk Investigational Site
Ostrava, , Czechia
Novo Nordisk Investigational Site
Ostrava, , Czechia
Novo Nordisk Investigational Site
Pilsen, , Czechia
Novo Nordisk Investigational Site
Prague, , Czechia
Novo Nordisk Investigational Site
Chartres, , France
Novo Nordisk Investigational Site
Courpière, , France
Novo Nordisk Investigational Site
Le Creusot, , France
Novo Nordisk Investigational Site
Lyon, , France
Novo Nordisk Investigational Site
Montélimar, , France
Novo Nordisk Investigational Site
Saint-Saëns, , France
Novo Nordisk Investigational Site
Sathonay-Camp, , France
Novo Nordisk Investigational Site
Strasbourg, , France
Novo Nordisk Investigational Site
Tarare, , France
Novo Nordisk Investigational Site
Vénissieux, , France
Novo Nordisk Investigational Site
Albano Laziale, , Italy
Novo Nordisk Investigational Site
Ariano Irpino, , Italy
Novo Nordisk Investigational Site
Bagno a Ripoli, , Italy
Novo Nordisk Investigational Site
Brindisi, , Italy
Novo Nordisk Investigational Site
Catanzaro, , Italy
Novo Nordisk Investigational Site
Fano, , Italy
Novo Nordisk Investigational Site
Ferrara, , Italy
Novo Nordisk Investigational Site
Florence, , Italy
Novo Nordisk Investigational Site
Messina, , Italy
Novo Nordisk Investigational Site
Milan, , Italy
Novo Nordisk Investigational Site
Napoli, , Italy
Novo Nordisk Investigational Site
Negrar (VR), , Italy
Novo Nordisk Investigational Site
Orvieto, , Italy
Novo Nordisk Investigational Site
Partinico (PA), , Italy
Novo Nordisk Investigational Site
Ravenna, , Italy
Novo Nordisk Investigational Site
Roma, , Italy
Novo Nordisk Investigational Site
Rozzano (MI), , Italy
Novo Nordisk Investigational Site
Savigliano (CN), , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, Dieuzeide G, Eriksen KT, Hong T, Kaltoft MS, Lengyel C, Rhee NA, Russo GT, Shirabe S, Urbancova K, Vencio S; CAPTURE Study Investigators. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021 Jul 27;20(1):154. doi: 10.1186/s12933-021-01344-0.
Vencio S, Vianna AGD, da Silva MACF, Precoma DB. Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study. Diabetol Metab Syndr. 2022 Jan 10;14(1):5. doi: 10.1186/s13098-021-00775-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1207-2816
Identifier Type: OTHER
Identifier Source: secondary_id
NN2211-4423
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.